Investors Research Corp Sells 2,216 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Investors Research Corp reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,536 shares of the biopharmaceutical company's stock after selling 2,216 shares during the period. Investors Research Corp's holdings in Gilead Sciences were worth $1,066,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Ranch Capital Advisors Inc. raised its position in Gilead Sciences by 57.7% during the fourth quarter. Ranch Capital Advisors Inc. now owns 19,555 shares of the biopharmaceutical company's stock valued at $1,806,000 after acquiring an additional 7,153 shares in the last quarter. Independent Advisor Alliance increased its stake in shares of Gilead Sciences by 35.4% during the 4th quarter. Independent Advisor Alliance now owns 32,128 shares of the biopharmaceutical company's stock worth $2,968,000 after purchasing an additional 8,398 shares during the last quarter. Johnson Investment Counsel Inc. lifted its stake in shares of Gilead Sciences by 10.3% in the 4th quarter. Johnson Investment Counsel Inc. now owns 16,629 shares of the biopharmaceutical company's stock valued at $1,536,000 after purchasing an additional 1,549 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of Gilead Sciences by 13.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 344,783 shares of the biopharmaceutical company's stock valued at $31,847,000 after purchasing an additional 39,700 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Gilead Sciences by 66.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,411,679 shares of the biopharmaceutical company's stock worth $130,397,000 after buying an additional 563,444 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 293,356 shares of company stock worth $29,166,240 over the last 90 days. Company insiders own 0.16% of the company's stock.

Gilead Sciences Stock Down 1.8 %

GILD traded down $2.09 on Tuesday, hitting $115.12. 7,647,636 shares of the company were exchanged, compared to its average volume of 8,160,293. The stock's fifty day moving average is $100.12 and its 200-day moving average is $91.91. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $143.37 billion, a PE ratio of 311.18, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is 854.05%.

Analyst Ratings Changes

A number of research analysts recently weighed in on GILD shares. Wolfe Research started coverage on Gilead Sciences in a research note on Friday, November 15th. They issued an "outperform" rating and a $110.00 price objective on the stock. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research note on Tuesday. Bank of America raised their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Finally, Citigroup began coverage on Gilead Sciences in a research report on Thursday, November 14th. They issued a "buy" rating and a $125.00 price target on the stock. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.